Ausgabe Sonderheft 3/2009
Controversies in Breast Cancer 2009
Inhalt (25 Artikel)
Section introduction
Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2
Ian E Smith
Short communication
Tailored targeted therapy for all: a realistic and worthwhile objective?
Per Eystein Lønning
Short communication
Tailored targeted therapy for all: a realistic and worthwhile objective against
Kathleen I Pritchard
Section introduction
The potential of new technologies/approaches. Introduction to Sessions 3 and 4
Mitch Dowsett
Short communication
Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
Sabine Riethdorf, Klaus Pantel
Section introduction
Who would have thought it! Influence on outcome of radiotherapy, Ki67 and stroma. Introduction to Session 5
Alan Rodger
Short communication
Who would have thought a single Ki67 measurement would predict long-term outcome?
Mitch Dowsett, Roger A'Hern, Janine Salter, Lila Zabaglo, Ian E Smith
Short communication
Breast tumour stroma is a prognostic indicator and target for therapy
Anthony Howell, Goran Landberg, Jonas Bergh
Short communication
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Ian E Smith
Section introduction
Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8
Stephen RD Johnston
Short communication
Are current drug development programmes realising the full potential of new agents? The scenario
Stephen RD Johnston
Short communication
The role of preclinical animal models in breast cancer drug development
Robert Clarke
Short communication
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
Eleanor Gutteridge, John FR Robertson
Short communication
Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy
Serena Di Cosimo